<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01117649</url>
  </required_header>
  <id_info>
    <org_study_id>HC-G-H-0803</org_study_id>
    <nct_id>NCT01117649</nct_id>
  </id_info>
  <brief_title>Plasma Volume Replacement (PVR) Therapy With Colloid and Crystalloid Solutions</brief_title>
  <official_title>Prospective, Controlled, Double-blind, Randomized Multi-centric Study on the Efficacy and Safety of a Target Controlled PVR Therapy With a Hyperoncotic Balanced Hydroxyethyl Starch (HES) Solution Versus an Isooncotic Balanced HES Solution Compared to a Balanced Electrolyte Solution in Elective Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>B. Braun Melsungen AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>B. Braun Melsungen AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy of target controlled fluid therapy
      with a hyper-oncotic balanced HES solution compared to an iso-oncotic HES solution in
      patients undergoing elective surgery of the pancreatic head. A third group receiving a
      balanced electrolyte solution (without colloidal volume replacement) will serve as a control
      for descriptive analysis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>First endpoint: Intraoperatively required amount of HES (10%, 6%) (ml)</measure>
    <time_frame>up to 8 hours</time_frame>
    <description>Goal-directed (stroke volume) plasma volume therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Second endpoint: Time until fully on oral (solid) diet (days)</measure>
    <time_frame>up to 15 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>haemodynamics, arterial blood gas analysis, laboratory data, postoperative nausea and vomiting, adverse events, nursing delirium screening scale, several injury scores</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Plasma Volume Replacement</condition>
  <condition>Surgery of the Pancreatic Head</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hyper-oncotic colloid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>iso-oncotic colloid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>crystalloid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HES 10%</intervention_name>
    <description>HES 10% dissolved in plasma adapted Ringer's solution (balanced solution).</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HES 6%</intervention_name>
    <description>HES 6% dissolved in plasma adapted Ringer's solution (balanced solution)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>balanced electrolyte solution</intervention_name>
    <description>plasma adapted Ringer's solution</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  patients scheduled to undergo elective surgery of the pancreatic head

          -  patients who are willing to give of voluntary consent to participate in the study,
             following a full explanation of the nature and purpose of the study, by signing the
             informed consent form approved by the Institutional Ethics Committee (IEC) prior to
             all evaluations.

        Exclusion:

          -  patients of American Society of Anesthesiologists (ASA) class &gt; III

          -  heart failure defined as New York Heart Association (NYHA) class&gt;2

          -  aneurysm of the ascending and thoracic aorta

          -  patients with Zenker's diverticle

          -  local oesophageal disease (oesophageal stricture, oesophageal varices, previous
             oesophageal surgery in past 6 months before study inclusion, pharyngeal pouch)

          -  patients receiving haemodialysis

          -  patients with known bleeding diatheses

          -  any bleeding disorder known from patient's history

          -  patients with a haematocrit &lt;= 25% despite pre-operative transfusion

          -  renal insufficiency (serum creatinine &gt; 130 µmol/l or &gt;1.5 mg/dl) or oliguria or
             anuria

          -  impaired hepatic function defined as Mayo End-Stage Liver Disease (MELD) &gt; 10 or liver
             cirrhosis Child-Pugh B or C

          -  additional contra-indications for investigational products
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudia Spies, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für Anästhesie und operative Intensivmedizin, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinik für Anästhesie und operative Intensivmedizin, Charité-Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Anästhesie, operative Intensivmedizin und Schmerztherapie, Humboldt Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13509</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2010</study_first_submitted>
  <study_first_submitted_qc>May 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2010</study_first_posted>
  <last_update_submitted>December 22, 2016</last_update_submitted>
  <last_update_submitted_qc>December 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PVR</keyword>
  <keyword>HES 130</keyword>
  <keyword>pancreatic head</keyword>
  <keyword>goal-directed</keyword>
  <keyword>intraoperative PVR in elective surgery of the pancreatic head</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

